Back To Search Instructions
Protocols
17 protocols meet the specified criteria
Phase: 1
Protocol No.TitleStatus
1502661845A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the treatment of multiple Metastases (NRG-BR001)Open
1603472947Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1607750114A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of JNJ-64052781 with Ibrutinib in Subjects with B-Cell MalignanciesNot Open
1609875338A Phase 1 Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous PF-06747143, Administered as Single Agent or in Combination with Standard Chemotherapy in Adult Patients with Acute Myeloid LeukemiaOpen
1611031060A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of TherapyOpen
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
1612074879An Open-Label, Multicenter, Dose Escalation, Phase IA/IB Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)Open
1612098443An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize theEffects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects with B-cell Lymphomas or Advanced Solid TumorsOpen
1701157446METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1702242206A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced MalignanciesOpen
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
1705469245A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic CancersOpen
1706595817A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1b CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMAOpen
1708698450A Phase 1b Study of Intratumoral IMO-2125 in Patients with Refractory Solid TumorsOpen
PHXE-16-0073-80-15A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIESOpen